Lowering Menin to help certain types of AML
Targeting Menin Protein Stability In AML
This work looks at ways to reduce the Menin protein in specific forms of acute myeloid leukemia so Menin-targeting drugs work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11299054 on NIH RePORTER |
What this research studies
Researchers are examining how Menin protein levels affect leukemia cells using laboratory models and patient-derived samples. They will identify the cellular machinery that controls Menin stability and test whether reducing Menin makes leukemia cells more sensitive to Menin-blocking drugs. The team will perform molecular experiments and screens to find proteins or enzymes that push Menin toward destruction. Results will inform new combination approaches that could be tested in future clinical trials.
Who could benefit from this research
Good fit: People with AML driven by MLL1 rearrangements, NPM1 mutations, or NUP98 rearrangements are the most relevant group for this work.
Not a fit: Patients whose leukemia is not related to Menin-driven genetic changes, or those seeking an immediate treatment option, are unlikely to benefit directly from this preclinical research.
Why it matters
Potential benefit: If successful, this could improve how well Menin-blocking drugs work and lead to new combination treatments for certain AML patients.
How similar studies have performed: Early clinical trials of Menin inhibitors have shown promise, but deliberately targeting Menin protein stability is a newer, mainly preclinical strategy that has not yet been proven in patients.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Cutler, Jevon — Oregon Health & Science University
- Study coordinator: Cutler, Jevon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.